<DOC>
	<DOCNO>NCT00003667</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Biological therapy use different way stimulate immune system stop cancer cell grow . Combining chemotherapy biological therapy may kill tumor cell . PURPOSE : Randomized phase II trial study effectiveness combination chemotherapy without biological therapy treat patient newly diagnose high-risk Ewing 's sarcoma .</brief_summary>
	<brief_title>Combination Chemotherapy Biological Therapy Treating Patients With High-Risk Ewing 's Sarcoma</brief_title>
	<detailed_description>OBJECTIVES : I . Compare effect dose intensive regimen vincristine , doxorubicin , cyclophosphamide , dexrazoxane without ImmTher ( muramyl dipeptide liposome ) 2 year disease-free survival patient newly diagnose high risk Ewing 's sarcoma . II . Evaluate feasibility determine toxicity administer weekly ImmTher 1 year patient . III . Determine therapy worthy evaluation . OUTLINE : This randomize study . Patients stratify accord presence bony metastases diagnosis . Patients randomize one two treatment arm . All patient receive dexrazoxane IV follow 30 minute later doxorubicin IV 30 minute day 1 , vincristine IV day 1 , cyclophosphamide IV 6 hour day 1 2 . Treatment repeat every 3 week 3-6 course absence disease progression unacceptable toxicity . Patients evaluate course 3 undergo surgery and/or radiation therapy . The next 3 course chemotherapy administer recovery surgery/radiation therapy . Within 1 month completion chemotherapy course , patient randomize arm I receive ImmTher IV 60 minute weekly 1 year . Patients randomize arm II receive therapy . Patients follow every 6 week 2 year . PROJECTED ACCRUAL : A total 105 patient accrue study within approximately 5 year .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Ewing</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Dexrazoxane</mesh_term>
	<mesh_term>Razoxane</mesh_term>
	<mesh_term>Acetylmuramyl-Alanyl-Isoglutamine</mesh_term>
	<mesh_term>Glycerol</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven high risk Ewing 's family tumor : Ewing 's sarcoma bone Extraosseous Ewing 's sarcoma Peripheral neuroepithelioma Must one follow characteristic : Metastatic disease diagnosis Primary tumor humerus , femur , trunk Bulky ( great 8 cm ) tumor Elevated LDH prior biopsy ( least 900 IU/mL ) PATIENT CHARACTERISTICS : Age : 3 60 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Granulocyte count least 500/mm3 Platelet count least 75,000/mm3 Hemoglobin least 8 g/dL ( transfusion allow ) Hepatic : Bilirubin great 1.5 mg/dL SGOT SGPT great 3 time normal Renal : BUN le 30 mg/dL Creatinine great 1.5 time normal age OR Creatinine clearance least 70 mL/min Cardiovascular : Ejection fraction least 50 % OR Fractional shorten least 29 % Other : Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>nonmetastatic childhood soft tissue sarcoma</keyword>
	<keyword>metastatic childhood soft tissue sarcoma</keyword>
	<keyword>extraosseous Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
	<keyword>localize Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
	<keyword>metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
</DOC>